Tory P Johnson1, Avindra Nath. 1. Section of Infections of the Nervous System, National Institute of Neurological Disorders and Stroke, National Institutes of Health, Bethesda, Maryland, USA.
Abstract
PURPOSE OF REVIEW: To highlight the importance of immune reconstitution inflammatory syndrome affecting the brain in HIV-infected individuals in the absence of opportunistic infections. To describe the varied clinical manifestations, unifying pathophysiological features and discuss the principles of management of this syndrome. RECENT FINDINGS: Immune reconstitution inflammatory syndrome within the brain is commonly seen in patients with HIV infection upon initiation of antiretroviral drugs. The fulminant forms occur in the face of opportunistic infections or uncontrolled viral replication within the brain. In this case, the enhanced immune response is targeted against the microbial agent, and the brain suffers bystander damage. Treatment requires the combination of the antimicrobial agent, continued antiretrovirals and in some cases corticosteroids. It is increasingly being recognized that despite adequate control of viral replication in the brain, some patients develop a chronic form of T cell encephalitis which appears to be driven by continued production of HIV-Tat protein. In others, the immune response may be targeted against the host antigens in the brain. SUMMARY: In patients with central nervous system-immune reconstitution inflammatory syndrome, the use of corticosteroids and strategies that prevent T cell migration into the brain may be needed. Extreme caution is necessary if viral eradication strategies are to be employed that involve activation of viral reservoirs, as these patients may be at risk for developing central nervous system-immune reconstitution inflammatory syndrome.
PURPOSE OF REVIEW: To highlight the importance of immune reconstitution inflammatory syndrome affecting the brain in HIV-infected individuals in the absence of opportunistic infections. To describe the varied clinical manifestations, unifying pathophysiological features and discuss the principles of management of this syndrome. RECENT FINDINGS: Immune reconstitution inflammatory syndrome within the brain is commonly seen in patients with HIV infection upon initiation of antiretroviral drugs. The fulminant forms occur in the face of opportunistic infections or uncontrolled viral replication within the brain. In this case, the enhanced immune response is targeted against the microbial agent, and the brain suffers bystander damage. Treatment requires the combination of the antimicrobial agent, continued antiretrovirals and in some cases corticosteroids. It is increasingly being recognized that despite adequate control of viral replication in the brain, some patients develop a chronic form of T cell encephalitis which appears to be driven by continued production of HIV-Tat protein. In others, the immune response may be targeted against the host antigens in the brain. SUMMARY: In patients with central nervous system-immune reconstitution inflammatory syndrome, the use of corticosteroids and strategies that prevent T cell migration into the brain may be needed. Extreme caution is necessary if viral eradication strategies are to be employed that involve activation of viral reservoirs, as these patients may be at risk for developing central nervous system-immune reconstitution inflammatory syndrome.
Authors: Christina C Chang; Saleha Omarjee; Andrew Lim; Tim Spelman; Bernadett I Gosnell; William H Carr; Julian H Elliott; Mohamed-Yunus S Moosa; Thumbi Ndung'u; Martyn A French; Sharon R Lewin Journal: J Infect Dis Date: 2013-08-01 Impact factor: 5.226
Authors: Igor Grant; Donald R Franklin; Reena Deutsch; Steven P Woods; Florin Vaida; Ronald J Ellis; Scott L Letendre; Thomas D Marcotte; J H Atkinson; Ann C Collier; Christina M Marra; David B Clifford; Benjamin B Gelman; Justin C McArthur; Susan Morgello; David M Simpson; John A McCutchan; Ian Abramson; Anthony Gamst; Christine Fennema-Notestine; Davey M Smith; Robert K Heaton Journal: Neurology Date: 2014-05-09 Impact factor: 9.910
Authors: Gottfried Hirnschall; Anthony D Harries; Philippa J Easterbrook; Meg C Doherty; Andrew Ball Journal: J Int AIDS Soc Date: 2013-06-30 Impact factor: 5.396
Authors: Ferdous Kadri; Marco Pacifici; Anna Wilk; Amanda Parker-Struckhoff; Luis Del Valle; Kurt F Hauser; Pamela E Knapp; Christopher Parsons; Duane Jeansonne; Adam Lassak; Francesca Peruzzi Journal: J Biol Chem Date: 2015-11-03 Impact factor: 5.157
Authors: Lisa M Mangus; Sarah E Beck; Suzanne E Queen; Samuel A Brill; Erin N Shirk; Kelly A Metcalf Pate; Dillon C Muth; Robert J Adams; Lucio Gama; Janice E Clements; Joseph L Mankowski Journal: Am J Pathol Date: 2017-12-08 Impact factor: 5.770
Authors: Eunice Patarata; Vera Bernardino; Ana Martins; Rui Pereira; Conceição Loureiro; Maria Francisca Moraes-Fontes Journal: Case Rep Neurol Date: 2016-12-13
Authors: Laura A Benjamin; Theresa J Allain; Henry Mzinganjira; Myles D Connor; Colin Smith; Sebastian Lucas; Elizabeth Joekes; Sam Kampondeni; Karen Chetcuti; Ian Turnbull; Mark Hopkins; Steve Kamiza; Elizabeth L Corbett; Robert S Heyderman; Tom Solomon Journal: J Infect Dis Date: 2017-09-01 Impact factor: 5.226